Overview

A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism

Status:
Recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper gastrointestinal, hepatobiliary, or pancreatic cancer, based on a group sequential design. Enrolled patients will be randomized in a 1:1 ratio. Patients will be stratified by performance status, type of cancer, chemotherapy and medical centers.

Phase:

Phase 2

Details

Lead Sponsor:

Asan Medical Center

Treatments:

Anticoagulants
Apixaban
Dalteparin
Heparin, Low-Molecular-Weight
Rivaroxaban
Tinzaparin